Boston Scientific Corporation has received CE mark approval for the Ranger paclitaxel-coated percutaneous transluminal angioplasty balloon catheter. The technology is now in full European market launch. The Ranger drug-coated balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.
“The Ranger drug-coated balloon offers tremendous promise and will provide another important tool to treat both above-the-knee and below-the-knee lesions,” says Dierk Scheinert, director, Center of Vascular Medicine, Angiology and Vascular Surgery at Park Krankenhaus, Leipzig, Germany. “When using contemporary technologies, a significant amount of drug coating can be lost during the handling, insertion and delivery of the device. I am excited by the technology in the Ranger drug-coated balloon, which has the potential to reduce drug loss significantly while optimising both deliverability and the absorption of the drug in the targeted tissue.”
According to Boston Scientific, the Ranger drug-coated balloon combines the deliverability of the market-leading Sterling balloon platform and the proven drug paclitaxel with advanced technologies designed to address the delicate and often unstable nature of the coating associated with contemporary drug-coated balloons. The Ranger drug-coated balloon features proprietary TransPax coating technology and an innovative loading tool designed to maintain drug-coating integrity and maximise drug-transfer efficiency resulting in consistent and predictable drug delivery.
